Linkedin Twitter

WG3: Translational medicine

Activities

This WG will pave the way towards a succesful transition from the preclinical to the clinical development of NRF2-targeted compounds. In this stage it is essential to identify reliable NRF2-related biomarkers to monitor disease progression and therapy outcome, equivalent both in patients and animal models. Thus, the main aim of WG3 will be to elaborate the template for future clinical trials on lead compounds identified in WG2 and to coordinate NRF2-related genetic and biochemical biomarker discovery in the selected NCDs.

Task

  • Identification of NRF2-related genetic and biochemical biomarkers using available databases of NCD patients and, in collaboration with WG2, identification of animal models of NCDs that faithfully replicate these human biomarkers.
  • Documentation of the panel of somatic mutations in the KEAP1/NRF2 system in non-small lung cancer that can be detected by cfDNA.
  • Documentation of clinical NFE2L2 genetic variants and endophenotypes, as well as drug response/resistance phenotypes of patients suffering from the subset of NCDs where NRF2 alterations have been identified;
  • Documentation of NRF2-related blood biomarkers and the design of a clinically-relevant biochip
  • Elaboration of the preliminary documentation for future clinical trials with compounds identified in WG2, that demonstrate efficacy in relevant animal models that replicate alterations in NRF2 pathophysiology.

Members

A. Suha Yalcin

  • Marmara University School of Medicine
  • Turkey (TR)
  • Website

Aleksandra Piechota-Polańczyk

  • Jagiellonian University
  • Poland (PL)

Aleksandra Zeljkovic

  • Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade
  • Serbia (RS)
  • Website

Ana Casas Guijarro

  • MAASTRICHT UNIVERSITY
  • Netherlands (NL)
  • Website

Andreas Daiber

  • University Medical Center of the Johannes Gutenberg University Mainz
  • Germany (DE)

Ángel Carracedo

  • Fundación Pública Galega de Medicina Xenómica
  • Spain (ES)

Anton Terasmaa

  • National Institute of Chemical Physics and Biophysics
  • Estonia (EE)

Arif Kamil Salihoğlu

  • Karadeniz Technical University Faculty of Medicine
  • Turkey (TR)

Arno Bourgonje

  • University Medical Center Groningen
  • Netherlands (NL)

Artyom Pugachev

  • ProteiQ Biosciences GmbH
  • Germany (DE)
  • Website

ASAF MARKO

  • The Hebrew University of Jerusalem
  • Israel (IL)
  • Website

Birsen Can Demirdöğen

  • TOBB University of Economics and Technology
  • Turkey (TR)

Brigitte Winklhofer-Roob

  • Karl-Franzens Universität Graz
  • Austria (AT)

Bruno Ramos-Molina

  • Biomedical Research Institute of Murcia (IMIB-Arrixaca)
  • Spain (ES)

Camillo Rosano

  • IRCCS AOU San Martino - IST National Institute for Cancer Research
  • Italy (IT)

Chakradhara Rao S Uppugunduri

  • University of Geneva
  • Switzerland (CH)

Danijela Djukic-Cosic

  • University of Belgrade - Faculty of Pharmacy
  • Serbia (RS)

Eugenia Carvalho

  • Center for Neuroscience and Cell Biology
  • Portugal (PT)

Eva Cano

  • Instituto de Salud Carlos III. Chronic Disease Programme
  • Spain (ES)

George Spyrou

  • The Cyprus Institute of Neurology and Genetics
  • Cyprus (CY)

Gerasimos Sykiotis

  • Lausanne University Hospital
  • Switzerland (CH)

Gina DeNicola

  • H. Lee Moffitt Cancer Center and Research Institute
  • United States (US)

Harry van Goor

  • University of Groningen
  • Netherlands (NL)
  • Website

Helena Vieira

  • UCIBIO| NOVA School of Science and Technology| Universidade Nova de Lisboa
  • Portugal (PT)

Ioannis Habeos

  • University of Patras, School of Medicine
  • Greece (EL)

Ioannis P. Trougakos

  • National & Kapodistrian University of Athens
  • Greece (EL)

Isabel Lastres-Becker

  • Universidad Autónoma de Madrid
  • Spain (ES)

Isabel Varela-Nieto

  • Consejo Superior de Investigaciones Cientificas (CSIC)
  • Spain (ES)

IVANA STOJANOVIC

  • Institute for Biological Research "Sinisa Stankovic"
  • Serbia (RS)
  • Website

Joana Loureiro

  • Faculty of Engineering| University of Porto
  • Portugal (PT)

Jordi Muntané

  • Hospital Universitario "Virgen del Rocío"
  • Spain (ES)

Josep Julve

  • Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
  • Spain (ES)
  • Website

Juan Antonio Moreno

  • IMIBIC| Cordoba University
  • Spain (ES)
  • Website

Katarina Baralić

  • University of Belgrade - Faculty of Pharmacy
  • Serbia (RS)

Katja Kanninen

  • A.I.Virtanen Institute for Molecular Sciences
  • Finland (FI)

Maria Carmo Pereira

  • Faculdade de Engenharia da Universidade do Porto
  • Portugal (PT)

Maria J Sanchez Quintero

  • Institute of Biomedical Research in Malaga (IBIMA)
  • Spain (ES)

Michel-Edwar Mickael

  • philopater Macavious Enskild firma (PM)
  • Egypt (EG)
  • Website

Miguel Seabra

  • CEDOC - Chronic Diseases Research Center| NOVA Medical School / Universidade Nova de Lisboa
  • Portugal (PT)

Milen Georgiev

  • The Stephan Angeloff Institute of Microbiology
  • Bulgaria (BG)

Natalija Jonić

  • Institute for Biological Research "Siniša Stanković"
  • Serbia (RS)
  • Website

Neda Djedovic

  • Institute for Biological Research "Siniša Stanković"- National Institute of Republic of Serbia, University of Belgrade
  • Serbia (RS)

Niki Chondrogianni

  • Institute of Chemical Biology
  • Greece (EL)
  • Website

Noemi Rotllan Vila

  • Biomedical Research Institute Sant Pau
  • Spain (ES)

Roberta Foresti

  • Institut Mondor de Recherche Biomédicale
  • France (FR)
  • Website

Roberto Motterlini

  • University Paris Est-INSERM U955
  • France (FR)
  • Website

Sara Zakaria

  • Vem İlaç San. ve Tic. A.Ş.
  • Turkey (TR)
  • Website

Sibel Kalyoncu Uzunlar

  • Izmir Biomedicine and Genome Center
  • Turkey (TR)

Sofia Azeredo Pereira

  • NOVA MEDICAL SCHOOL| Universidade NOVA de Lisboa
  • Portugal (PT)

Susana Cadenas

  • Centro de Biología Molecular Severo Ochoa (CSIC/UAM)
  • Spain (ES)

Suzana Stanisavljevic

  • Institute for Biological Research "Siniša Stanković"
  • Serbia (RS)

Tamara Gojkovic

  • Faculty of Pharmacy, University of Belgrade
  • Serbia (RS)
  • Website

Ugne Jonavice

  • State Research Institute Centre for Innovative Medicine
  • Lithuania (LT)
  • Website

Vera Marisa Costa

  • Toxicology Lab| Faculty of Pharmacy UP
  • Portugal (PT)

Vita Dolzan

  • University of Ljubljana| Faculty of Medicine
  • Slovenia (SI)
  • Website

Yahya Sohrabi

  • Dept. of Cardiology I – Coronary and Peripheral Vascular Disease
  • Germany (DE)

Subscribe to our newsletter

COST

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.

BenBedPhar CA20121

Action details

Grant Holder: Universidad Autónoma de Madrid
Start of Action: 19 October, 2021
End of Action: 18 October, 2025
CSO approval date: 25 May 2021
Action email: info@benbedphar.org

© 2022 BenBedPhar | Design by Tuinbit Group